Post-hoc analysis of clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis (IPF) by elevated autoantibody (AAb) status
C. Newton (Dallas, United States), T. Kulkarni (Birmingham, United States), K. Samara (Basel, Switzerland), J. Ko (South San Francisco, United States), S. Gupta (South San Francisco, United States), E. Bernstein (New York, United States), A. Samara (Athens, Greece)
Source: International Congress 2022 – How to prevent progression in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Newton (Dallas, United States), T. Kulkarni (Birmingham, United States), K. Samara (Basel, Switzerland), J. Ko (South San Francisco, United States), S. Gupta (South San Francisco, United States), E. Bernstein (New York, United States), A. Samara (Athens, Greece). Post-hoc analysis of clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis (IPF) by elevated autoantibody (AAb) status. 2662
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|